HL-08

Primary objective: To evaluate the efficacy of different doses of HL08 (0.75mg, 1.5mg and 3mg) subcutaneously injected once a week (QW) in patients with T2DM whose blood glucose is poorly controlled by diet and exercise alone, based on the change in glycated hemoglobin (HbA1c) from baseline to week 12. Secondary objectives: To evaluate the safety of different doses of HL08 in patients with T2DM. To evaluate the blood glucose regulation effect of different doses of HL08 in patients with T2DM. To evaluate the population pharmacokinetic (PopPK) characteristics of HL08 in patients with T2DM. To evaluate the immunogenicity of HL08 in patients with T2DM.